Thomas Civik - 12 Aug 2026 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: Interim CEO, Director
Issuer ticker: PYXS
Reported as of: 12 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 16:06:09 UTC
Prior SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Thomas Civik

Key filing fact

Thomas Civik filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 14 Aug 2026.

Key facts

This page summarizes Thomas Civik's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2026, 16:06.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001723092 Primary reporting owner

Civik Thomas

Relationship: Interim CEO, Director
Address: C/O PYXIS ONCOLOGY, INC., 321 HARRISON AVENUE, 11TH FL. SUITE 1, BOSTON
Signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Thomas Civik
Signature date: 14 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +250,956
Change %: +36%
Price: $0.000000^*
Shares after: 941,087
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,956
Exercise price: $1.49
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the performance-based portion of an option that was granted on February 3, 2026, which shares subject to this portion of the option were to become vested in full upon the completion of a successful financing transaction or a successful strategic transaction during the reporting person's continued service as Interim Chief Executive Officer or within six months thereafter. The performance conditions were deemed to have been met on August 12, 2026, as determined by the Board.